Gilead to Acquire PepStar Oral IL-23R Program for $1.275 Billion
Gilead agreed to acquire the program from privately held PepStar Therapeutics for $1.275 billion in cash, gaining worldwide rights to its lead asset, HCXT-2001.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Gilead to Acquire PepStar’s HCXT-2001 IL-23R Inhibitor Program
Gilead Sciences entered a definitive agreement to acquire PepStar Therapeutics’ oral IL-23R inhibitor program, including lead asset HCXT-2001.